vs

Side-by-side financial comparison of EQUITY BANCSHARES INC (EQBK) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $63.5M, roughly 1.2× EQUITY BANCSHARES INC). EQUITY BANCSHARES INC runs the higher net margin — 34.8% vs -121.9%, a 156.7% gap on every dollar of revenue. On growth, EQUITY BANCSHARES INC posted the faster year-over-year revenue change (28.4% vs -6.2%). EQUITY BANCSHARES INC produced more free cash flow last quarter ($38.1M vs $9.6M). Over the past eight quarters, EQUITY BANCSHARES INC's revenue compounded faster (6.6% CAGR vs -0.0%).

Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

EQBK vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.2× larger
HCAT
$74.7M
$63.5M
EQBK
Growing faster (revenue YoY)
EQBK
EQBK
+34.5% gap
EQBK
28.4%
-6.2%
HCAT
Higher net margin
EQBK
EQBK
156.7% more per $
EQBK
34.8%
-121.9%
HCAT
More free cash flow
EQBK
EQBK
$28.5M more FCF
EQBK
$38.1M
$9.6M
HCAT
Faster 2-yr revenue CAGR
EQBK
EQBK
Annualised
EQBK
6.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EQBK
EQBK
HCAT
HCAT
Revenue
$63.5M
$74.7M
Net Profit
$22.1M
$-91.0M
Gross Margin
Operating Margin
41.7%
-115.3%
Net Margin
34.8%
-121.9%
Revenue YoY
28.4%
-6.2%
Net Profit YoY
30.0%
-340.3%
EPS (diluted)
$1.07
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EQBK
EQBK
HCAT
HCAT
Q4 25
$63.5M
$74.7M
Q3 25
$18.0M
$76.3M
Q2 25
$58.4M
$80.7M
Q1 25
$60.6M
$79.4M
Q4 24
$58.3M
$79.6M
Q3 24
$55.3M
$76.4M
Q2 24
$55.4M
$75.9M
Q1 24
$55.9M
$74.7M
Net Profit
EQBK
EQBK
HCAT
HCAT
Q4 25
$22.1M
$-91.0M
Q3 25
$-29.7M
$-22.2M
Q2 25
$15.3M
$-41.0M
Q1 25
$15.0M
$-23.7M
Q4 24
$17.0M
$-20.7M
Q3 24
$19.9M
$-14.7M
Q2 24
$11.7M
$-13.5M
Q1 24
$14.1M
$-20.6M
Gross Margin
EQBK
EQBK
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
EQBK
EQBK
HCAT
HCAT
Q4 25
41.7%
-115.3%
Q3 25
-207.2%
-22.9%
Q2 25
31.5%
-46.0%
Q1 25
31.1%
-25.4%
Q4 24
35.0%
-22.0%
Q3 24
43.1%
-17.9%
Q2 24
29.4%
-20.8%
Q1 24
31.8%
-30.5%
Net Margin
EQBK
EQBK
HCAT
HCAT
Q4 25
34.8%
-121.9%
Q3 25
-164.7%
-29.1%
Q2 25
26.1%
-50.8%
Q1 25
24.8%
-29.9%
Q4 24
29.1%
-26.0%
Q3 24
35.9%
-19.3%
Q2 24
21.1%
-17.8%
Q1 24
25.2%
-27.6%
EPS (diluted)
EQBK
EQBK
HCAT
HCAT
Q4 25
$1.07
$-1.29
Q3 25
$-1.55
$-0.32
Q2 25
$0.86
$-0.59
Q1 25
$0.85
$-0.35
Q4 24
$1.06
$-0.33
Q3 24
$1.28
$-0.24
Q2 24
$0.76
$-0.23
Q1 24
$0.90
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EQBK
EQBK
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$95.7M
Total DebtLower is stronger
$443.2M
$153.3M
Stockholders' EquityBook value
$732.1M
$245.8M
Total Assets
$6.4B
$502.6M
Debt / EquityLower = less leverage
0.61×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EQBK
EQBK
HCAT
HCAT
Q4 25
$95.7M
Q3 25
$91.5M
Q2 25
$97.3M
Q1 25
$342.0M
Q4 24
$392.0M
Q3 24
$387.3M
Q2 24
$308.3M
Q1 24
$327.8M
Total Debt
EQBK
EQBK
HCAT
HCAT
Q4 25
$443.2M
$153.3M
Q3 25
$486.9M
$153.1M
Q2 25
$448.4M
$153.0M
Q1 25
$376.9M
$382.9M
Q4 24
$312.8M
$382.4M
Q3 24
$437.5M
$345.0M
Q2 24
$391.7M
Q1 24
$367.1M
Stockholders' Equity
EQBK
EQBK
HCAT
HCAT
Q4 25
$732.1M
$245.8M
Q3 25
$711.9M
$331.9M
Q2 25
$635.6M
$347.5M
Q1 25
$617.3M
$376.8M
Q4 24
$592.9M
$365.2M
Q3 24
$504.0M
$355.0M
Q2 24
$461.4M
$357.0M
Q1 24
$456.8M
$357.2M
Total Assets
EQBK
EQBK
HCAT
HCAT
Q4 25
$6.4B
$502.6M
Q3 25
$6.4B
$587.1M
Q2 25
$5.4B
$616.2M
Q1 25
$5.4B
$891.5M
Q4 24
$5.3B
$858.9M
Q3 24
$5.4B
$813.0M
Q2 24
$5.2B
$691.7M
Q1 24
$5.2B
$695.1M
Debt / Equity
EQBK
EQBK
HCAT
HCAT
Q4 25
0.61×
0.62×
Q3 25
0.68×
0.46×
Q2 25
0.71×
0.44×
Q1 25
0.61×
1.02×
Q4 24
0.53×
1.05×
Q3 24
0.87×
0.97×
Q2 24
0.85×
Q1 24
0.80×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EQBK
EQBK
HCAT
HCAT
Operating Cash FlowLast quarter
$51.4M
$9.9M
Free Cash FlowOCF − Capex
$38.1M
$9.6M
FCF MarginFCF / Revenue
60.0%
12.9%
Capex IntensityCapex / Revenue
20.9%
0.4%
Cash ConversionOCF / Net Profit
2.33×
TTM Free Cash FlowTrailing 4 quarters
$88.8M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EQBK
EQBK
HCAT
HCAT
Q4 25
$51.4M
$9.9M
Q3 25
$8.5M
$-464.0K
Q2 25
$28.3M
$-9.0M
Q1 25
$21.7M
$280.0K
Q4 24
$73.8M
$-3.5M
Q3 24
$23.5M
$6.2M
Q2 24
$16.0M
$1.6M
Q1 24
$12.6M
$10.3M
Free Cash Flow
EQBK
EQBK
HCAT
HCAT
Q4 25
$38.1M
$9.6M
Q3 25
$4.5M
$-719.0K
Q2 25
$26.0M
$-9.2M
Q1 25
$20.2M
$-390.0K
Q4 24
$65.4M
$-3.9M
Q3 24
$19.7M
$5.5M
Q2 24
$15.2M
$1.3M
Q1 24
$10.6M
$10.1M
FCF Margin
EQBK
EQBK
HCAT
HCAT
Q4 25
60.0%
12.9%
Q3 25
24.7%
-0.9%
Q2 25
44.5%
-11.4%
Q1 25
33.3%
-0.5%
Q4 24
112.1%
-4.9%
Q3 24
35.6%
7.2%
Q2 24
27.4%
1.7%
Q1 24
19.0%
13.5%
Capex Intensity
EQBK
EQBK
HCAT
HCAT
Q4 25
20.9%
0.4%
Q3 25
22.3%
0.3%
Q2 25
3.9%
0.3%
Q1 25
2.4%
0.8%
Q4 24
14.6%
0.5%
Q3 24
6.8%
0.9%
Q2 24
1.5%
0.4%
Q1 24
3.6%
0.3%
Cash Conversion
EQBK
EQBK
HCAT
HCAT
Q4 25
2.33×
Q3 25
Q2 25
1.85×
Q1 25
1.44×
Q4 24
4.35×
Q3 24
1.18×
Q2 24
1.37×
Q1 24
0.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EQBK
EQBK

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons